#55 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Patients seeking cannabinoid-based treatments may find that the medicines with the strongest clinical evidence available elsewhere in the world remain inaccessible in the U.S. not because of safety concerns, but because of who is permitted to conduct the research in the first place.
The United States maintains a uniquely fragmented regulatory environment for cannabis research, where federal scheduling under the Controlled Substances Act creates structural barriers that foreign operators and even domestic companies struggle to navigate when developing cannabinoid-based medicines. Unlike pharmaceuticals that can be studied and approved through relatively standardized international pathways, cannabis research in the U.S. requires federal authorization at multiple levels, creating a system where control over the science is inseparable from control over the market. This regulatory architecture effectively determines not just who can sell cannabis medicines in the U.S., but who can generate the clinical evidence needed to legitimize them globally.
“When federal law decides who gets to ask the scientific questions, it has already decided who gets to profit from the answers, and that is a research integrity problem before it is a market problem.”
The regulatory fragmentation between state-legal cannabis programs and federal scheduling creates a significant barrier to rigorous drug development that ultimately impacts patient access to standardized, evidence-based cannabinoid therapeutics. While state markets have expanded rapidly, the absence of federal oversight means most products lack the quality controls and clinical validation that physicians typically expect from pharmaceutical interventions. This divide incentivizes companies to pursue easier pathways through unregulated state channels rather than undertaking the costly research necessary to establish safety and efficacy profiles. Until cannabinoid-based medicines can be studied under unified federal frameworks, clinicians will continue operating with limited comparative data and patients may miss opportunities for truly therapeutic dosing and formulation strategies. The market’s current structure prioritizes commercial scale over clinical rigor, which is the inverse of what evidence-based medicine requires.
๐ฌ Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan โ
Want to discuss this topic with other patients and caregivers? Join the forum discussion โ
Have thoughts on this? Share it: